{"id":36561,"date":"2025-07-03T14:53:50","date_gmt":"2025-07-03T06:53:50","guid":{"rendered":"https:\/\/flcube.com\/?p=36561"},"modified":"2025-07-03T14:53:51","modified_gmt":"2025-07-03T06:53:51","slug":"changchun-genesciences-firsekibart-receives-nmpa-approval-for-acute-gouty-arthritis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36561","title":{"rendered":"Changchun GeneScience&#8217;s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis"},"content":{"rendered":"\n<p>China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its Category 1 drug firsekibart from the National Medical Products Administration (NMPA). The drug is indicated for adult patients with acute gouty arthritis attacks who are contraindicated for, intolerant of, or unresponsive to NSAIDs and\/or colchicine, and are unsuitable for repeated corticosteroid use. This marks the first IL-1\u03b2 monoclonal antibody (mAb) approved in China for this condition.<\/p>\n\n\n\n<p><strong>Clinical Advantages<\/strong><br>Firsekibart demonstrates three key clinical advantages: long-term control, rapid and potent efficacy, and high safety. By precisely blocking IL-1\u03b2, the key inflammatory mediator in gout, the drug shows outstanding therapeutic effects.<\/p>\n\n\n\n<p><strong>Phase III Trial Results<\/strong><br>Results from Phase III multicenter, randomized, double-blind, active-controlled clinical trials indicate that firsekibart provides rapid relief after a single dose. The analgesic effects are comparable to corticosteroids within 6-72 hours, and the drug reduces the risk of first recurrence within 6 months by 87%. Additionally, no drug-related serious adverse reactions were observed.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36562,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[358,15],"class_list":["post-36561","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-genescience-pharmaceutical","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun GeneScience&#039;s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its Category 1 drug firsekibart from the National Medical Products Administration (NMPA). The drug is indicated for adult patients with acute gouty arthritis attacks who are contraindicated for, intolerant of, or unresponsive to NSAIDs and\/or colchicine, and are unsuitable for repeated corticosteroid use. This marks the first IL-1\u03b2 monoclonal antibody (mAb) approved in China for this condition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36561\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun GeneScience&#039;s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis\" \/>\n<meta property=\"og:description\" content=\"China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its Category 1 drug firsekibart from the National Medical Products Administration (NMPA). The drug is indicated for adult patients with acute gouty arthritis attacks who are contraindicated for, intolerant of, or unresponsive to NSAIDs and\/or colchicine, and are unsuitable for repeated corticosteroid use. This marks the first IL-1\u03b2 monoclonal antibody (mAb) approved in China for this condition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36561\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-03T06:53:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-03T06:53:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0304.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun GeneScience&#8217;s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis\",\"datePublished\":\"2025-07-03T06:53:50+00:00\",\"dateModified\":\"2025-07-03T06:53:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561\"},\"wordCount\":173,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0304.webp\",\"keywords\":[\"GeneScience Pharmaceutical\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36561#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36561\",\"name\":\"Changchun GeneScience's Firsekibart Receives NMPA Approval for Acute Gouty Arthritis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0304.webp\",\"datePublished\":\"2025-07-03T06:53:50+00:00\",\"dateModified\":\"2025-07-03T06:53:51+00:00\",\"description\":\"China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its Category 1 drug firsekibart from the National Medical Products Administration (NMPA). The drug is indicated for adult patients with acute gouty arthritis attacks who are contraindicated for, intolerant of, or unresponsive to NSAIDs and\\\/or colchicine, and are unsuitable for repeated corticosteroid use. This marks the first IL-1\u03b2 monoclonal antibody (mAb) approved in China for this condition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36561\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0304.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0304.webp\",\"width\":1080,\"height\":608,\"caption\":\"Changchun GeneScience's Firsekibart Receives NMPA Approval for Acute Gouty Arthritis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36561#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun GeneScience&#8217;s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun GeneScience's Firsekibart Receives NMPA Approval for Acute Gouty Arthritis - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its Category 1 drug firsekibart from the National Medical Products Administration (NMPA). The drug is indicated for adult patients with acute gouty arthritis attacks who are contraindicated for, intolerant of, or unresponsive to NSAIDs and\/or colchicine, and are unsuitable for repeated corticosteroid use. This marks the first IL-1\u03b2 monoclonal antibody (mAb) approved in China for this condition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36561","og_locale":"en_US","og_type":"article","og_title":"Changchun GeneScience's Firsekibart Receives NMPA Approval for Acute Gouty Arthritis","og_description":"China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its Category 1 drug firsekibart from the National Medical Products Administration (NMPA). The drug is indicated for adult patients with acute gouty arthritis attacks who are contraindicated for, intolerant of, or unresponsive to NSAIDs and\/or colchicine, and are unsuitable for repeated corticosteroid use. This marks the first IL-1\u03b2 monoclonal antibody (mAb) approved in China for this condition.","og_url":"https:\/\/flcube.com\/?p=36561","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-03T06:53:50+00:00","article_modified_time":"2025-07-03T06:53:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0304.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36561#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36561"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun GeneScience&#8217;s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis","datePublished":"2025-07-03T06:53:50+00:00","dateModified":"2025-07-03T06:53:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36561"},"wordCount":173,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36561#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0304.webp","keywords":["GeneScience Pharmaceutical","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36561#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36561","url":"https:\/\/flcube.com\/?p=36561","name":"Changchun GeneScience's Firsekibart Receives NMPA Approval for Acute Gouty Arthritis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36561#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36561#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0304.webp","datePublished":"2025-07-03T06:53:50+00:00","dateModified":"2025-07-03T06:53:51+00:00","description":"China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its Category 1 drug firsekibart from the National Medical Products Administration (NMPA). The drug is indicated for adult patients with acute gouty arthritis attacks who are contraindicated for, intolerant of, or unresponsive to NSAIDs and\/or colchicine, and are unsuitable for repeated corticosteroid use. This marks the first IL-1\u03b2 monoclonal antibody (mAb) approved in China for this condition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36561#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36561"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36561#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0304.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0304.webp","width":1080,"height":608,"caption":"Changchun GeneScience's Firsekibart Receives NMPA Approval for Acute Gouty Arthritis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36561#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun GeneScience&#8217;s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0304.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36561"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36561\/revisions"}],"predecessor-version":[{"id":36563,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36561\/revisions\/36563"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36562"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}